nusinersen


( Last Updated : June 12, 2020)
Generic Name:
nusinersen
Project Status:
Complete
Therapeutic Area:
Spinal Muscular Atrophy
Manufacturer:
Biogen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Spinraza
Project Line:
Reimbursement Review
Project Number:
SR0525-000
Call for patient/clinician input closed:

Details

Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Spinal Muscular Atrophy
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Call for patient input postedJune 01, 2017
Patient group input closedJuly 21, 2017
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 27, 2017
Patient group comments on input summary closedAugust 04, 2017
Clarification:

- Patient input summary feedback received

Submission receivedJune 28, 2017
Submission acceptedJuly 13, 2017
Review initiatedJuly 14, 2017
Draft CADTH review report(s) sent to sponsorOctober 02, 2017
Comments from sponsor on draft CADTH review report(s) receivedOctober 12, 2017
Redaction requests from sponsor on draft CADTH review report(s) receivedOctober 19, 2017
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 03, 2017
Canadian Drug Expert Committee (CDEC) meetingNovember 15, 2017
CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plansNovember 29, 2017
Embargo period ended and validation of redacted CADTH review report(s) receivedDecember 13, 2017
CDEC Final Recommendation issued to sponsor and drug plansDecember 20, 2017
CDEC Final Recommendation postedDecember 22, 2017
Final CADTH review report(s) and patient input postedJanuary 10, 2018

Files

Recommendations and Reasons

Clinical Report

Pharmacoeconomic Report

Patient Input Summary